A former world champion middle-distance runner from Belarus has been temporarily suspended for doping after testing positive for a drug that has been in clinical trials to treat muscle wasting.
The Athletics Integrity Unit (AIU) said on August 27 that 31-year-old Marina Arzamasova has been notified of the allegation, one month before the world championships in Qatar.
The AIU was formed by the International Association of Athletics Federations (IAAF) in April 2017 to combat doping in the sport of athletics.
Arzamasova's case involves LGD-4033, better known as Ligandrol, the AIU said. Ligandrol is reportedly used in supplements by body builders to build muscle mass with fewer side effects than steroids.
Arzamasova won the 800 meters at the 2015 world championships in Beijing and was European champion in 2014. She placed seventh at the 2016 Rio de Janeiro Olympics.
The AIU operates fully independently from the IAAF.
Former Belarusian World Champion Runner Suspended For Doping
Editors' Picks
Top Trending
1
After Her Photo Went Viral, Maria Zaytsava Was Killed Fighting For Ukraine
2What's Stopping NATO Countries From Boosting Defense Spending?
3Moscow's War On Ukraine: Where's The Russian Outrage?
4Trump Warns Putin For Third Time To End 'Ridiculous' Ukraine War
5Trump Says Putin ‘Destroying’ Russia By Failing To Seek Ukraine Peace Deal
6Could Trump Cut A Deal With Putin And Leave Ukraine In The Cold?
7Why Are European Troops For Ukraine A Nonstarter?
8Ukraine Live Briefing: Russia Targets Civilian Infrastructure
9Amid Russian Assault, Ukrainian Children Evacuated From Pokrovsk
102 Iranian Supreme Court Judges Killed In Tehran
RFE/RL has been declared an "undesirable organization" by the Russian government.
If you are in Russia or the Russia-controlled parts of Ukraine and hold a Russian passport or are a stateless person residing permanently in Russia or the Russia-controlled parts of Ukraine, please note that you could face fines or imprisonment for sharing, liking, commenting on, or saving our content, or for contacting us.
To find out more, click here.
